Becton, Dickinson and Company

NYSE BDX

Becton, Dickinson and Company EBITDA for the Trailing 12 Months (TTM) ending September 30, 2024: USD 4.26 B

Becton, Dickinson and Company EBITDA is USD 4.26 B for the Trailing 12 Months (TTM) ending September 30, 2024, a -0.26% change year over year. EBITDA means earnings before interest, taxes, depreciation, and amortization, which measures a company's operating performance by excluding non-operating expenses.
  • Becton, Dickinson and Company EBITDA for the Trailing 12 Months (TTM) ending September 30, 2023 was USD 4.27 B, a 1.02% change year over year.
  • Becton, Dickinson and Company EBITDA for the Trailing 12 Months (TTM) ending September 30, 2022 was USD 4.23 B, a -15.13% change year over year.
  • Becton, Dickinson and Company EBITDA for the Trailing 12 Months (TTM) ending September 30, 2021 was USD 4.98 B, a 35.93% change year over year.
  • Becton, Dickinson and Company EBITDA for the Trailing 12 Months (TTM) ending September 30, 2020 was USD 3.67 B, a -9.60% change year over year.
Key data
Date EBITDA Net Income EPS (Diluted) Shares (Diluted, Weighted)
Market news
Loading...
NYSE: BDX

Becton, Dickinson and Company

CEO Mr. Thomas E. Polen Jr.
IPO Date Feb. 21, 1973
Location United States
Headquarters 1 Becton Drive
Employees 70,000
Sector Health Care
Industries
Description

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is based in Franklin Lakes, New Jersey.

Similar companies

HAE

Haemonetics Corporation

USD 79.96

0.69%

RGEN

Repligen Corporation

USD 156.55

-1.19%

COO

The Cooper Companies, Inc.

USD 89.11

-2.38%

TFX

Teleflex Incorporated

USD 179.17

0.35%

WST

West Pharmaceutical Services, Inc.

USD 328.96

-3.13%

RMD

ResMed Inc.

USD 228.83

-0.62%

XRAY

DENTSPLY SIRONA Inc.

USD 18.06

-3.21%

ICUI

ICU Medical, Inc.

USD 161.08

1.85%

HOLX

Hologic, Inc.

USD 70.20

-0.13%

ANGO

AngioDynamics, Inc.

USD 11.80

-5.30%

StockViz Staff

January 15, 2025

Any question? Send us an email